DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Paul Biondi - 1 Biondi - 1 Mikael Dolsten - 1 Foghorn - 1 Bhanvi - 1 Michael Erman - 1 Shilpi Majumdar - 1 Alexandra Hudson - 1
Top related locs:
Bengaluru New Jersey
Top related orgs:
drugmaker Pfizer - 1 Moderna Inc - 1 Pfizer - 1 Flagship's - 1 Bristol Myers Squibb - 1 Flagship - 1 Therapeutics - 1 Foghorn Therapeutics - 1

Search resuls for: "Sana Biotechnology"


3 mentions found


☆ Pfizer, Flagship Pioneering to invest $100 mln in drug discovery
  + stars: | 2023-07-18 | by ( ) www.reuters.com   time to read: +2 min
July 18 (Reuters) - U.S. drugmaker Pfizer (PFE.N) and venture firm Flagship Pioneering on Tuesday said they would invest $100 million together to develop up to 10 new potential drugs for areas including internal medicine, oncology, infectious diseases and immunology. Flagship, which has incubated biotech companies, most famously Moderna Inc (MRNA.O), and Pfizer will each invest $50 million. Flagship's drug discovery initiative Pioneering Medicines will lead the exploration process. Paul Biondi, president of Flagship's Pioneering unit and a former top Bristol Myers Squibb (BMY.N) executive, said the partnership will take advantage of Flagship's abilities to develop novel technologies towards bigger disease areas. Drug developers such as Denali Therapeutics (DNLI.O), Foghorn Therapeutics (FHTX.O) and Sana Biotechnology (SANA.O) are some of the other companies backed by Flagship.
Persons: Paul Biondi, Biondi, Mikael Dolsten, Foghorn, Bhanvi, Michael Erman, Shilpi Majumdar, Alexandra Hudson Organizations: drugmaker Pfizer, Moderna Inc, Pfizer, Flagship's, Bristol Myers Squibb, Flagship, Therapeutics, Foghorn Therapeutics, Sana Biotechnology, Alexandra Hudson Our, Thomson Locations: Bengaluru, New Jersey
☆ The most shorted names on Wall Street include a plant-based food stock and five biotechs
  + stars: | 2023-03-28 | by ( Nick Wells Sarah Min | Nick Wells | Sarah Min | ) www.cnbc.com   time to read: +2 min
As of March 15, short interest against Tattooed Chef rose nearly 4% to 17.1 million shares, which is about 35% of the total float, according to FactSet data. The percentage of float refers to the number of shares that are sold short divided by the the total number of shares available for trading. Short interest in another plant-based food company, Beyond Meat, remained elevated even after falling slightly by 2.5% to around 21 million shares. Other companies that saw a surge in short interest this month include a number of biotech companies. In the first half of March, investors increased their bets against Allogene Therapeutics by about 8% to 39.8 million shares, or about half its total float.
☆ Analysis: Biotech IPOs to bloom with spotlight on startups with human trial data
  + stars: | 2023-02-13 | by ( Amruta Khandekar Bhanvi Satija | Amruta Khandekar | Bhanvi Satija | ) www.reuters.com   time to read: +5 min
Globally, IPOs across all sectors nosedived last year after a blockbuster 2021, as aggressive interest rate hikes by central banks to curb inflation put an end to the era of cheap money. In the biotech sector, there were only 47 IPOs last year that raised a total of about $4 billion, compared with 152 offerings in 2021 that had raised over $25 billion. While the XBI is still trading 50% below its February 2021 closing high, analysts believe the downturn in biotech has bottomed out. All we need is one or two biotech IPOs to get good interest and the floodgates will open." Reuters GraphicsThe second half of 2023 is more likely to see a significant step-up in biotech IPOs instead of the first half, as markets await further clarity on potential rate cuts, analysts said.
0 next >>
Total: 3